Literature DB >> 23379494

Antibody response after single H1N1 influenza vaccine in chronic dialysis patients.

Alper Azak1, Bülent Huddam, Gülay Kocak, A Basak Altas, Murat Duranay, Gülay Korukluoglu.   

Abstract

The first influenza pandemic of this century happened through a rapid spread of a novel swine-derived H1N1 influenza virus. Vaccines are produced in order to avoid the infection. Children and other high risk groups are highly recommended for vaccination due to the high probability of contracting the virus. Chronic kidney disease patients were also accepted as a risk group and vaccination of all patients undergoing hemodialysis or peritoneal dialysis was recommended. The results of H1N1 influenza virus vaccine on patients receiving hemodialysis and peritoneal dialysis are analyzed. Antibody titers of both hemodialysis and peritoneal dialysis patients were elevated after vaccination. Peritoneal dialysis patients responded better.
© 2012 The Authors. Therapeutic Apheresis and Dialysis © 2012 International Society for Apheresis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23379494     DOI: 10.1111/j.1744-9987.2012.01133.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  2 in total

Review 1.  Prophylactic vaccinations in chronic kidney disease: Current status.

Authors:  Alicja E Grzegorzewska
Journal:  Hum Vaccin Immunother       Date:  2015-04-27       Impact factor: 3.452

2.  Local and Systemic Immunity Are Impaired in End-Stage-Renal-Disease Patients Treated With Hemodialysis, Peritoneal Dialysis and Kidney Transplant Recipients Immunized With BNT162b2 Pfizer-BioNTech SARS-CoV-2 Vaccine.

Authors:  Magdalena Piotrowska; Maciej Zieliński; Leszek Tylicki; Bogdan Biedunkiewicz; Alicja Kubanek; Zuzanna Ślizień; Karolina Polewska; Piotr Tylicki; Marta Muchlado; Justyna Sakowska; Marcin Renke; Adam Sudoł; Małgorzata Dąbrowska; Monika Lichodziejewska-Niemierko; Tomasz Smiatacz; Alicja Dębska-Ślizień; Piotr Trzonkowski
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.